Get the latest news, insights, and market updates on PROF (Profound Medical Corp.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Wall Street Analysts Believe Profound Medical (PROF) Could Rally 97.59%: Here's is How to Trade
The consensus price target hints at a 97.6% upside potential for Profound Medical (PROF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. Nov 19, 2025 - $PROF
Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease
Renowned urologist Dr. Mark Hong sets new global benchmark for urologist-led, MRI-guided prostate treatment, leading a growing movement toward incision-free prostate therapyTORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, announced today that The Hong Center Scottsdale, led b Nov 18, 2025 - $PROF
Profound Medical Reports Strong Third Quarter 2025 Financial Results
TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the third quarter ended September 30, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. ge Nov 13, 2025 - $PROF
Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates
Profound Medical (PROF) delivered earnings and revenue surprises of +31.58% and +0.74%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 13, 2025 - $PROF
Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand
TORONTO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, announced today that it has entered into an exclusive distribution and supply agreement for its TULSA-PRO® system with Getz Healthcare, a leading distributor of medical devices, equipment and consumables, in Australia and New Z Nov 12, 2025 - $PROF
Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia
Agreement creates runway for Profound’s incision-free and radiation-free therapies for the ablation of diseased tissue, to penetrate the largest healthcare market in the Middle East All required regulatory approvals to import and sell Profound’s two advanced ablative technologies in Saudi Arabia are already in place TORONTO and RIYADH, Saudi Arabia, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device com Nov 11, 2025 - $PROF
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple